{
  "run_id": "RUN_20260204_210740_ca2647f10a08",
  "timestamp": "2026-02-04T22:10:35.113581",
  "document": "Acquired-Lipodystrophy.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/test/Acquired-Lipodystrophy.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 11,
  "total_validated": 11,
  "total_rejected": 0,
  "total_ambiguous": 0,
  "diseases": [
    {
      "matched_text": "acquired generalized lipodystrophy",
      "preferred_label": "acquired generalized lipodystrophy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019193",
        "orpha": "Orphanet:79086",
        "umls": "UMLS:C0271693",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019193",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0080300",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:12603",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:543499",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:1200860",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C131089",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:79086",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:86907008",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0271693",
          "display": null
        }
      ],
      "context": "her acquired at some point during life. Acquired lipodystrophies do not have a direct genetic cause, but rather many different factors may be involved. Acquired lipodystrophies can be caused by medications, autoimmunity or for unknown reasons (idiopathic). Subtypes of acquired lipodystrophy include acquired generalized lipodystrophy (Lawrence syndrome), acquired partial lipodystrophy (Barraquer-Simons syndrome), localized lipodystrophy, and high active antiretroviral induced lipodystrophy, which may develop in HIV-infected individuals undergoing a specific form of treatment. Onset of acquired forms of lipodystrophy can occur d",
      "page": 1,
      "mention_count": 2,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "acquired partial lipodystrophy",
      "preferred_label": "acquired partial lipodystrophy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0012104",
        "orpha": "Orphanet:79087",
        "umls": "UMLS:C0220989",
        "mesh": "MESH:C562448"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0012104",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:10509",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:66352",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:C562448",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:1200862",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C129723",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:79087",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:75659004",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0220989",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:2042663302",
          "display": null
        }
      ],
      "context": "trophies do not have a direct genetic cause, but rather many different factors may be involved. Acquired lipodystrophies can be caused by medications, autoimmunity or for unknown reasons (idiopathic). Subtypes of acquired lipodystrophy include acquired generalized lipodystrophy (Lawrence syndrome), acquired partial lipodystrophy (Barraquer-Simons syndrome), localized lipodystrophy, and high active antiretroviral induced lipodystrophy, which may develop in HIV-infected individuals undergoing a specific form of treatment. Onset of acquired forms of lipodystrophy can occur during childhood, adolescence or adulthood. Affected",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Lipodystrophy Partial Acquired",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "Barraquer-Simons syndrome",
      "preferred_label": "barraquer-simons syndrome",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0100476",
        "orpha": null,
        "umls": "UMLS:C3887501",
        "mesh": "C562448"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0100476",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:854363",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:608709",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C3887501",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C562448",
          "display": "Lipodystrophy Partial Acquired"
        }
      ],
      "context": "netic cause, but rather many different factors may be involved. Acquired lipodystrophies can be caused by medications, autoimmunity or for unknown reasons (idiopathic). Subtypes of acquired lipodystrophy include acquired generalized lipodystrophy (Lawrence syndrome), acquired partial lipodystrophy (Barraquer-Simons syndrome), localized lipodystrophy, and high active antiretroviral induced lipodystrophy, which may develop in HIV-infected individuals undergoing a specific form of treatment. Onset of acquired forms of lipodystrophy can occur during childhood, adolescence or adulthood. Affected individuals develop charact",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Lipodystrophy Partial Acquired",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "localized lipodystrophy",
      "preferred_label": "localized lipodystrophy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0019194",
        "orpha": "Orphanet:79088",
        "umls": "UMLS:C4329999",
        "mesh": null
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0019194",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:5867",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:1385527",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C131814",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:79088",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C4329999",
          "display": null
        }
      ],
      "context": "different factors may be involved. Acquired lipodystrophies can be caused by medications, autoimmunity or for unknown reasons (idiopathic). Subtypes of acquired lipodystrophy include acquired generalized lipodystrophy (Lawrence syndrome), acquired partial lipodystrophy (Barraquer-Simons syndrome), localized lipodystrophy, and high active antiretroviral induced lipodystrophy, which may develop in HIV-infected individuals undergoing a specific form of treatment. Onset of acquired forms of lipodystrophy can occur during childhood, adolescence or adulthood. Affected individuals develop characteristic loss of body fat (",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "Acquired lipodystrophies",
      "preferred_label": "acquired lipodystrophy",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0020089",
        "orpha": "Orphanet:98307",
        "umls": "UMLS:C0877192",
        "mesh": "C562448"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0020089",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:12602",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:798705",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10049287",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:98307",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0877192",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C562448",
          "display": "Lipodystrophy Partial Acquired"
        }
      ],
      "context": "Acquired lipodystrophy is a general term for types of lipodystrophy that are not inherited, but rather acquired at some point during life. Acquired lipodystrophies do not have a direct genetic cause, but rather many different factors may be involved. Acquired lipodystrophies can be caused by medications, autoimmunity or for unknown reasons (idiopathic). Subtypes of acquired lipodystrophy include acquired generalized lipodystrophy (Lawrence syndrome), acquired",
      "page": 1,
      "mention_count": 2,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Lipodystrophy Partial Acquired",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "hypertriglyceridemia",
      "preferred_label": "hypertriglyceridemia",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005347",
        "orpha": null,
        "umls": "UMLS:C0813230",
        "mesh": "MESH:D015228"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005347",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0004211",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0002155",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:167238",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D015228",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:302870006",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0813230",
          "display": null
        }
      ],
      "context": "ially the arms, legs, face, neck, and chest or thoracic regions. In some cases, metabolic complications associated with insulin resistance can develop. Such complications include an inability to break down glucose (glucose intolerance), elevated levels of triglycerides (a type of fat) in the blood (hypertriglyceridemia), and diabetes. Additional symptoms such as fat accumulation in the liver (fatty liver or hepatic steatosis) may also occur. AGL and APL generally affect women more than men, although this may be due in part to ascertainment bias because women tend to be more severely affected and more easily recog",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Hyperlipoproteinemia Type I",
        "Hyperlipoproteinemia Type IV"
      ],
      "pubtator_normalized_name": "Hypertriglyceridemia",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "glucose intolerance",
      "preferred_label": "glucose intolerance",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0001076",
        "orpha": null,
        "umls": "UMLS:C0271650",
        "mesh": "MESH:D018149"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0001076",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:10603",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:271.3",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:75760",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D018149",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C34646",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:267426009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0271650",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:1392580302",
          "display": null
        }
      ],
      "context": "eristic loss of body fat (adipose tissue) affecting specific areas of the body, especially the arms, legs, face, neck, and chest or thoracic regions. In some cases, metabolic complications associated with insulin resistance can develop. Such complications include an inability to break down glucose (glucose intolerance), elevated levels of triglycerides (a type of fat) in the blood (hypertriglyceridemia), and diabetes. Additional symptoms such as fat accumulation in the liver (fatty liver or hepatic steatosis) may also occur. AGL and APL generally affect women more than men, although this may be due in part to as",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Glucose-Galactose Malabsorption"
      ],
      "pubtator_normalized_name": "Glucose Intolerance",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "lipodystrophy",
      "preferred_label": "lipodystrophy",
      "abbreviation": null,
      "confidence": 0.85,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0006573",
        "orpha": null,
        "umls": "UMLS:C0023787",
        "mesh": "MESH:D008060"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0006573",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:811",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:1000727",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0009125",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:272.6",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:6111",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D008060",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200404",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C97093",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:71325002",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0023787",
          "display": null
        },
        {
          "system": "Wikipedia",
          "code": "Wikipedia:Lipodystrophy",
          "display": null
        }
      ],
      "context": "Acquired lipodystrophy is a general term for types of lipodystrophy that are not inherited, but rather acquired at some point during life. Acquired lipodystrophies do not have a direct genetic cause, but rather many different factors may be involved. Acquired lipodystrophies can be caused by medications, autoimmunity or for unknown reasons (idiopathic). Subtypes of",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Lipodystrophy Familial Partial",
        "Lipodystrophy Congenital Generalized",
        "SHORT syndrome"
      ],
      "pubtator_normalized_name": "Lipodystrophy",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "fatty liver",
      "preferred_label": "fatty liver",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "gastroenterology",
      "codes": {
        "icd10": null,
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0004790",
        "orpha": null,
        "umls": "UMLS:C2711227",
        "mesh": "MESH:D005234"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0004790",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:9452",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:571.8",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:398225",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D005234",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:371330000",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C2711227",
          "display": null
        }
      ],
      "context": "cations associated with insulin resistance can develop. Such complications include an inability to break down glucose (glucose intolerance), elevated levels of triglycerides (a type of fat) in the blood (hypertriglyceridemia), and diabetes. Additional symptoms such as fat accumulation in the liver (fatty liver or hepatic steatosis) may also occur. AGL and APL generally affect women more than men, although this may be due in part to ascertainment bias because women tend to be more severely affected and more easily recognized. APL has been reported in approximately 250 individuals with a male to female rat",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Fatty Liver",
        "Fatty Liver Alcoholic",
        "Acute fatty liver of pregnancy"
      ],
      "pubtator_normalized_name": "Non-alcoholic Fatty Liver Disease",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "diabetes",
      "preferred_label": "diabetes",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": "endocrinology",
      "codes": {
        "icd10": "ICD10CM:E08-E13",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0005015",
        "orpha": null,
        "umls": "UMLS:C0011849",
        "mesh": "MESH:D003920"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0005015",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:9351",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000400",
          "display": null
        },
        {
          "system": "HP",
          "code": "HP:0000819",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:E08-E13",
          "display": null
        },
        {
          "system": "ICD10WHO",
          "code": "ICD10WHO:E10-E14",
          "display": null
        },
        {
          "system": "ICD9",
          "code": "ICD9:250",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:8350",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D003920",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2100158",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C2985",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:73211009",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0011849",
          "display": null
        },
        {
          "system": "icd11.foundation",
          "code": "icd11.foundation:465177735",
          "display": null
        }
      ],
      "context": "neck, and chest or thoracic regions. In some cases, metabolic complications associated with insulin resistance can develop. Such complications include an inability to break down glucose (glucose intolerance), elevated levels of triglycerides (a type of fat) in the blood (hypertriglyceridemia), and diabetes. Additional symptoms such as fat accumulation in the liver (fatty liver or hepatic steatosis) may also occur. AGL and APL generally affect women more than men, although this may be due in part to ascertainment bias because women tend to be more severely affected and more easily recognized. APL has",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Diabetes Mellitus Type 2",
        "Diabetes Mellitus Type 1",
        "Diabetes Gestational"
      ],
      "pubtator_normalized_name": "Diabetes Mellitus",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "APL",
      "preferred_label": "APL",
      "abbreviation": null,
      "confidence": 0.95,
      "is_rare_disease": false,
      "category": null,
      "codes": {
        "icd10": "ICD10CM:C92.4",
        "icd11": null,
        "snomed": null,
        "mondo": "MONDO:MONDO_0012883",
        "orpha": "Orphanet:520",
        "umls": "UMLS:C0023487",
        "mesh": "MESH:D015473"
      },
      "all_identifiers": [
        {
          "system": "MONDO",
          "code": "MONDO_0012883",
          "display": null
        },
        {
          "system": "DOID",
          "code": "DOID:0081081",
          "display": null
        },
        {
          "system": "EFO",
          "code": "EFO:0000224",
          "display": null
        },
        {
          "system": "GARD",
          "code": "GARD:538",
          "display": null
        },
        {
          "system": "ICD-10-CM",
          "code": "ICD10CM:C92.4",
          "display": null
        },
        {
          "system": "ICDO",
          "code": "ICDO:9866/3",
          "display": null
        },
        {
          "system": "MEDGEN",
          "code": "MEDGEN:44127",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "MESH:D015473",
          "display": null
        },
        {
          "system": "MedDRA",
          "code": "MedDRA:10001019",
          "display": null
        },
        {
          "system": "NANDO",
          "code": "NANDO:2200007",
          "display": null
        },
        {
          "system": "NCIT",
          "code": "NCIT:C3182",
          "display": null
        },
        {
          "system": "NORD",
          "code": "NORD:2003",
          "display": null
        },
        {
          "system": "OMIM",
          "code": "OMIM:612376",
          "display": null
        },
        {
          "system": "Orphanet",
          "code": "Orphanet:520",
          "display": null
        },
        {
          "system": "SCTID",
          "code": "SCTID:110004001",
          "display": null
        },
        {
          "system": "UMLS",
          "code": "UMLS:C0023487",
          "display": null
        }
      ],
      "context": "ch complications include an inability to break down glucose (glucose intolerance), elevated levels of triglycerides (a type of fat) in the blood (hypertriglyceridemia), and diabetes. Additional symptoms such as fat accumulation in the liver (fatty liver or hepatic steatosis) may also occur. AGL and APL generally affect women more than men, although this may be due in part to ascertainment bias because women tend to be more severely affected and more easily recognized. APL has been reported in approximately 250 individuals with a male to female ratio of 1:4. It has been reported in individuals of",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_mondo_diseases.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "Ectodermal Dysplasia",
        "Aplasia of Lacrimal and Salivary Glands"
      ],
      "pubtator_normalized_name": "Anemia Aplastic",
      "enrichment_source": "pubtator3"
    }
  ]
}